Exterior of Astellas’ United States office, where teams develop innovative therapies with integrity and patient-first focus.

United States newsroom

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.

Month Year

Month Year

Dec 23, 2024

Astellas Pharma US, Inc. Issues Voluntary Nationwide Recall of One Lot of PROGRAF^® 0.5mg (tacrolimus) and One Lot of ASTAGRAF XL^® 0.5mg (tacrolimus extended-release capsules) because bottles shipped to U.S. may contain empty capsules

FOR IMMEDIATE RELEASE – NORTHBROOK, IL, Dec. 23, 2024 – Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") is voluntarily recalling one lot of PROGRAF® 0.5mg...

Read more about Astellas Pharma US, Inc. Issues Voluntary Nationwide Recall of One Lot of PROGRAF^® 0.5mg (tacrolimus) and One Lot of ASTAGRAF XL^® 0.5mg (tacrolimus extended-release capsules) because bottles shipped to U.S. may contain empty capsules
Dec 5, 2024

Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves

"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives. NORTHBROOK, Ill., Dec. 5, 2024 /PRNewswire/ -- Astellas Pharma...

Read more about Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves
Nov 20, 2024

Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA^TM for Heart Failure Management

SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare...

Read more about Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA^TM for Heart Failure Management
Oct 10, 2024

FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device

ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- iota Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today...

Read more about FDA Grants iota Biosciences IDE Approval for First-In-Human Early Feasibility Study with Implantable Bladder Device
Sep 5, 2024

Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies

The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners

Read more about Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies

Show per page

Discover more

Return to global media homepage

U.S.

Follow U.S. news

Subscribe to news alerts